EW vs. RGC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EW and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Symbol | EW | RGC |
---|---|---|
Company Name | Edwards Lifesciences Corporation | Regencell Bioscience Holdings Limited |
Country | United States | Hong Kong |
GICS Sector | Health Care | Health Care |
GICS Industry | Health Care Equipment & Supplies | Pharmaceuticals |
Market Capitalization | 45.61 billion USD | 6.64 billion USD |
Exchange | NYSE | NasdaqCM |
Listing Date | March 27, 2000 | July 16, 2021 |
Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EW and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
Symbol | EW | RGC |
---|---|---|
5-Day Price Return | -0.32% | 6.67% |
13-Week Price Return | 3.85% | 39.56% |
26-Week Price Return | 9.42% | 13,340.00% |
52-Week Price Return | 18.52% | 3,740.00% |
Month-to-Date Return | -2.06% | 1.82% |
Year-to-Date Return | 4.93% | 10,238.46% |
10-Day Avg. Volume | 3.55M | 0.31M |
3-Month Avg. Volume | 4.52M | 2.51M |
3-Month Volatility | 20.75% | 664.33% |
Beta | 1.05 | 2.35 |
Profitability
Return on Equity (TTM)
EW
41.25%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
EW’s Return on Equity of 41.25% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
RGC
-54.75%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
EW
72.96%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
EW’s Net Profit Margin of 72.96% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
RGC
--
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
Net Profit Margin data for RGC is currently unavailable.
Operating Profit Margin (TTM)
EW
25.01%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
An Operating Profit Margin of 25.01% places EW in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
RGC
--
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
Operating Profit Margin data for RGC is currently unavailable.
Profitability at a Glance
Symbol | EW | RGC |
---|---|---|
Return on Equity (TTM) | 41.25% | -54.75% |
Return on Assets (TTM) | 31.58% | -51.38% |
Net Profit Margin (TTM) | 72.96% | -- |
Operating Profit Margin (TTM) | 25.01% | -- |
Gross Profit Margin (TTM) | 78.87% | -- |
Financial Strength
Current Ratio (MRQ)
EW
4.68
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
EW’s Current Ratio of 4.68 is in the upper quartile for the Health Care Equipment & Supplies industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
RGC
42.68
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio (MRQ)
EW
0.06
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
Falling into the lower quartile for the Health Care Equipment & Supplies industry, EW’s Debt-to-Equity Ratio of 0.06 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
RGC
0.00
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
EW
3.15
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
In the lower quartile for the Health Care Equipment & Supplies industry, EW’s Interest Coverage Ratio of 3.15 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
RGC
--
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
Interest Coverage Ratio data for RGC is currently unavailable.
Financial Strength at a Glance
Symbol | EW | RGC |
---|---|---|
Current Ratio (MRQ) | 4.68 | 42.68 |
Quick Ratio (MRQ) | 3.79 | 41.89 |
Debt-to-Equity Ratio (MRQ) | 0.06 | 0.00 |
Interest Coverage Ratio (TTM) | 3.15 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EW
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
EW currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
EW
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
EW has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
Symbol | EW | RGC |
---|---|---|
Dividend Yield (TTM) | 0.00% | 0.00% |
Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
EW
10.90
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
EW’s P/E Ratio of 10.90 is below the typical range for the Health Care Equipment & Supplies industry. This may indicate that the stock is potentially undervalued, or it could reflect market concerns about the company’s future prospects.
RGC
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for RGC is currently unavailable.
Price-to-Sales Ratio (TTM)
EW
7.95
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
EW’s P/S Ratio of 7.95 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
RGC
--
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
P/S Ratio data for RGC is currently unavailable.
Price-to-Book Ratio (MRQ)
EW
4.35
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
EW’s P/B Ratio of 4.35 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
RGC
9.57
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
Symbol | EW | RGC |
---|---|---|
Price-to-Earnings Ratio (TTM) | 10.90 | -- |
Price-to-Sales Ratio (TTM) | 7.95 | -- |
Price-to-Book Ratio (MRQ) | 4.35 | 9.57 |
Price-to-Free Cash Flow Ratio (TTM) | 59.51 | -- |